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Abstract
Background: Stillbirth rates in the United Kingdom (UK) are amongst the highest of all developed nations. The
association between small-for-gestational-age (SGA) foetuses and stillbirth is well established, and observational
studies suggest that improved antenatal detection of SGA babies may halve the stillbirth rate. The Growth
Assessment Protocol (GAP) describes a complex intervention that includes risk assessment for SGA and
screening using customised fundal-height growth charts. Increased detection of SGA from the use of GAP has
been implicated in the reduction of stillbirth rates by 22%, in observational studies of UK regions where GAP
uptake was high. This study will be the first randomised controlled trial examining the clinical efficacy, health
economics and implementation of the GAP programme in the antenatal detection of SGA.
Methods/design: In this randomised controlled trial, clusters comprising a maternity unit (or National Health
Service Trust) were randomised to either implementation of the GAP programme, or standard care. The primary
outcome is the rate of antenatal ultrasound detection of SGA in infants found to be SGA at birth by both population
and customised standards, as this is recognised as being the group with highest risk for perinatal morbidity and
mortality. Secondary outcomes include antenatal detection of SGA by population centiles, antenatal detection of SGA
by customised centiles, short-term maternal and neonatal outcomes, resource use and economic consequences, and a
process evaluation of GAP implementation. Qualitative interviews will be performed to assess facilitators and barriers to
implementation of GAP.
Discussion: This study will be the first to provide data and outcomes from a randomised controlled trial investigating
the potential difference between the GAP programme compared to standard care for antenatal ultrasound detection
of SGA infants. Accurate information on the performance and service provision requirements of the GAP protocol has
the potential to inform national policy decisions on methods to reduce the rate of stillbirth.
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Background
The rate of stillbirth in England and Wales has declined
recently from 5.7/1000 births in 2003 to 4.7/1000 in
2013 [1] but the United Kingdom (UK) rate remains
amongst the highest in developed countries [2, 3]. Redu-
cing stillbirth is a national priority [4–6]. It has been es-
timated that up to 57% of babies who die in utero are
small for gestational age (SGA) and 9% have placental
insufficiency. However, rates are dependent upon which
perinatal classification system is used (32.6–57%) [7–9].
The use of routine screening achieves antenatal detec-
tion of SGA in approximately 20–25% of cases [10–13]. In
the UK, routine screening involves fundal-height measure-
ments in low-risk pregnancies and serial growth scans in
high-risk pregnancies; however, there is variation in risk
factors considered and frequency of assessment. Since the
publication of the National Health Service (NHS) England
‘Saving Babies’ Lives Care Bundle’ in 2017, there has been
a move towards consistency on risk factor stratification
[5]. Other strategies, such as universal third-trimester
ultrasound, could increase the antenatal detection of SGA
to 57% for nulliparous women with singleton pregnancies
[13]. A population-based study has reported that antenatal
detection of SGA may halve the risk of stillbirth through
appropriate antenatal surveillance and timely delivery
[10]. This suggests that improvements in the detection of
SGA infants could potentially result in further reduction
in the incidence of stillbirths.
SGA is traditionally defined as weight below the 10th
centile for gestational age and sex according to population
references [14, 15]. The development of population-based
centiles is an improvement over the use of estimated fetal
weight or absolute birthweight to characterise abnormal-
ities of fetal and infant growth. This is exemplified by a
2000-g neonate which will be considered small at term
(37–42 completed gestational weeks) but normally grown
at 32 weeks. SGA by population birthweight references ac-
count only for the physiological effects of gestational age
and fetal sex, and it has been hypothesised that there are
additional physiological maternal and fetal characteristics
that may affect fetal growth [16]. Some foetuses, currently
defined as SGA, may be appropriately grown for maternal
constitution (i.e. the constitutionally small foetus). Other
foetuses with impaired growth may still fall within the
normal range by population references, particularly if gen-
etically predetermined to be at higher centiles.
The concept of customised fetal growth standards at-
tempts to address these issues and is based on three
principles: (1) individualised (adjusted for physiological
factors that affect birth weight – maternal height,
weight, ethnicity, parity, fetal sex and gestation at deliv-
ery); (2) optimised growth potential (excluding patho-
logical factors affecting the weight standard such as
smoking and diabetes) and (3) use of fetal growth
curves, derived from normal pregnancies [17]. Inter-
national studies have demonstrated that the use of cus-
tomised standards identifies additional SGA foetuses,
which were not otherwise identified by population stan-
dards [18–22]. Infants who are SGA only by customised
standards are at increased risk of adverse outcomes, in-
cluding stillbirth [18]. These studies have also suggested
that foetuses that are considered SGA by population
references, but not by customised standards, have out-
comes similar to those of appropriately grown foetuses
[18–22]. A non-randomised study of the use of custo-
mised charts for fundal-height measurement and esti-
mated fetal weight demonstrated an increase in
antenatal detection of small babies (47.9% vs. 29.2%,
odds ratio 2.23; 95%CI 1.12–4.45) when compared to
routine care, but did not demonstrate differences in
other key perinatal outcomes, including for stillbirth
(five vs. four stillbirths: odds ratio 1.14 (95%CI 0.30–
4.25) [23]. Implementation of customised charts has also
been explored observationally in Australia where a
doubling in the detection rate of SGA was demonstrated
in nulliparous women, when compared with historical
controls [24].
The Growth Assessment Protocol (GAP) is a
programme developed by the Perinatal Institute that con-
sists of the use of gestation-related optimal weight
(GROW) customised charts, alongside a schedule of ante-
natal risk assessment for SGA, management protocols for
suspected SGA foetuses, audit tools and training [17].
GROW utilises a systematic method of measurement,
achieved through standardised training and accreditation,
with measurements plotted onto customised fundal-height
charts. Estimated fetal weights from ultrasound assess-
ment are also plotted onto these customised fetal growth
charts when growth scans are performed. The risk assess-
ment and management protocols were adapted from the
Royal College of Obstetricians and Gynaecologists
(RCOG) Green-top Guideline on Investigation and
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Management of the Small-for-Gestational-Age Foetus
[25]. The audit tool is aimed at identifying missed cases
and assessing the reasons for failure to antenatally recog-
nise the SGA foetus.
The use of the GAP/GROW programme has expanded
since its development and is now implemented in 121
(76%) UK Trusts [26]. A study in the UK compared re-
gions with high uptake to regions with low GAP uptake
during the period 2008 to 2012, using stillbirth data
from the Office for National Statistics’ records [1]. Over-
all, there was a 22% lower stillbirth rate in the
high-uptake regions during the period analysed, com-
pared to static rates in the low-uptake areas, although it
should be noted that the low-uptake regions had lower
rates to begin with (4.86 stillbirths/1000 births vs. 5.63/
1000 births in the high-uptake regions) and ecological
comparisons such as these cannot be assumed to re-
flect an effect of GAP and may instead reflect a num-
ber of changes over time [23]. For example, the
Mothers and Babies: Reducing Risk through Audits
and Confidential Enquiries across the UK (MBRRA-
CE-UK) Perinatal Mortality Surveillance Report (2013)
confirms a gradual decline in stillbirth rates across
the UK over a similar period (the decade up to 2013),
and attributes this to Sands (the Stillbirth and Neo-
natal Death charity) raising awareness of a number of
initiatives designed to reduce stillbirth rates, and/or
to new guidance from the UK Royal College of Ob-
stetricians and Gynaecologists in redefining which
stillborn babies require registration (i.e. not those
known to have died in utero prior to the end of the
24th gestational week) [3].
It is widely recognised that the highest level of evi-
dence for intervention effectiveness is obtained from
randomised controlled trials (RCTs), and a Cochrane re-
view has highlighted that these are currently lacking in
this area [27]. A RCT to accurately assess the GAP
programme is, therefore, imperative and timely. Further-
more, there is a paucity of data on the effect of GAP on
other maternal and neonatal outcomes such as caesarean
section rates, induction of labour, gestational age at de-
livery or on the use of clinical resources including ultra-
sound scan appointments, neonatal intensive care unit
(NICU) admission and lengths of maternal or neonatal
stay in hospital. These outcomes may have a significant
health-economic impact which must also be balanced
against any improvement in perinatal outcomes (still-
birth, early neonatal death, serious neonatal morbidity).
We propose a cluster RCT to evaluate the GAP
programme as a strategy for improving the antenatal detec-
tion of SGA, including an evaluation of the GAP imple-
mentation and a health economic assessment. This
protocol (version 7.0, dated 18 January 2018) has been writ-
ten and reported according to the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) guid-
ance and Checklist [28] (see Additional file 1: Table S1-S2).
Methods/design
Study objectives
The objectives are to: (1) determine whether implemen-
tation of the GAP programme will result in an improved
detection of SGA by ultrasound; (2) investigate the effect
of the intervention on short-term maternal and neonatal
outcomes; (3) estimate the impact of GAP on clinical
service provision and health economics and (4) assess fi-
delity and quality of implementation, acceptability and
identify contextual factors associated with variation in
the effect of GAP.
Trial design and setting
A cluster RCT will compare the detection rates of SGA
in hospitals randomised to the GAP programme to those
randomised to standard care (local policy for screening
and detection of abnormal fetal growth); see Fig. 1. Ma-
ternity units (some containing more than one site) were
approached on the basis that they were willing to intro-
duce GAP into their unit and were willing to be rando-
mised to the intervention (immediate implementation of
GAP) or standard care (implementation delayed at least
until the trial ends). Maternity units randomised to
standard care agreed that they would continue with
current practice until the completion of the data collec-
tion period, at which point they will have the opportun-
ity to implement GAP. Each UK Trust within the study
forms a cluster. We intend to test superiority of the
GAP in the antenatal detection of SGA by ultrasound.
A cluster RCT design has been chosen due to the na-
ture of the intervention. The GAP programme requires
culture change and retraining of multidisciplinary mater-
nity care staff; it is, therefore, not feasible to partially im-
plement GAP in a hospital and randomise individuals to
either study arm. The RCT was planned with the major-
ity of the sites in London, since uptake of the GAP
programme in this region was low at the start of the trial
and the London maternity network had recommended
the use of GAP regionally as a strategy to reduce still-
birth rates which were higher than the national average
(5.3/1000 in 2013 compared to 4.8/1000 in 2013 in Eng-
land and Wales [1]).
This is a pragmatic trial for which the intervention will
be introduced by the clinical care team with the support
of the Perinatal Institute (the only providers of training
in GAP/GROW). This approach captures the reality of
introducing a complex intervention into clinical practice
in these sites. See Fig. 2 for the trial timeline of enrol-
ment, intervention and assessment.
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Eligibility criteria
Eligibility criteria are based on the characteristics of the
maternity unit which is the unit of randomisation and
not on individual women. Data from all women who
give birth within an eligible maternity unit will be in-
cluded within the study unless individuals specifically
opt out of the study. Maternity units that have already
fully implemented GAP were not eligible. Data from
women with multiple pregnancies or fetal congenital ab-
normalities will be excluded from the analysis.
Interventions
Description and components
The study intervention is implementation of the GAP
programme (see Fig. 3) [17]. This includes cascading staff
training, adopting or refining evidence-based protocols for
SGA detection (Fig. 4), routine monitoring of SGA and
detection rates, regular audits of missed cases and ongoing
support between the Perinatal Institute and Trusts. Man-
agement for women in hospitals randomised to the imple-
mentation arm (GAP) is described in Table 1.
In the standard care arm, women will receive routine
care as per their current hospital practice on screening
and management of SGA (see Fig. 3). In the absence of
GAP, primary screening for anomalies of fetal growth in
the UK commonly includes fundal-height measurements
that are either plotted onto (non-customised) antenatal
growth charts or approximated to the gestational period.
Approximation to the gestational period refers to McDo-
nald’s rule, the number of centimetres is expected to ap-
proximately equal the gestational age in weeks (± 2–3
cm). The population chart in clinical use in the standard
care arm was not pre-specified.
The equation used to calculate the estimated fetal weight
based on ultrasound biometry was not pre-specified in the
study protocol for either arm of the trial, but Hadlock is the
most commonly used in the UK.
Training and accreditation – Training in GAP will be
provided by the Perinatal Institute, the only provider of
GAP and its training, to nominated trainers within each
cluster. These trainers will then be expected to dissemin-
ate this training to > 75% of multidisciplinary staff en-
gaged in antenatal care within their unit. E-learning and
assessment packages, as well as competency certificates,
are available to reinforce this. Each cluster will have the
uptake monitored via online training logs.
Audit – Routine quarterly reporting of SGA rates at
birth and its antenatal detection is considered an essen-
tial component of the GAP programme. Together with
the audit of missed cases of SGA, these feedback mecha-
nisms identify local issues and provide insight on im-
proving performance.
Support and communication – As a routine require-
ment for GAP implementation, Trusts are asked to
nominate link persons from each specialty (midwifery,
sonography and an obstetric/fetal medicine lead) who
will provide local leadership and liaise with the GAP
team at the Perinatal Institute.
Recruitment and allocation
We have already recruited 13 clusters to the trial. The first
eight clusters committing to participate were divided into
Fig. 1 Diagram of expected procedures in participating clusters in the intervention and standard care arms
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two strata of four clusters each according to their size
(number of deliveries during the year 2013–2014).
Two further strata (of three and then two) clusters
were subsequently defined for clusters that agreed to
participate in the study at later dates. For the stratum
of size 3 it was randomly determined that two clus-
ters would be allocated to intervention and one to
control rather than vice versa, and in all other strata
allocation was equally to intervention and control, so
that, in total, seven clusters have been allocated to
intervention and six to the control. Within-strata allo-
cation to intervention and control was by random
permutation using Stata v14 (StataCorp LP, College
Station, TX, USA). Due to the nature of the interven-
tion, concealment is not possible.
Retention and compliance
Regular meetings of GAP leads have been arranged dur-
ing implementation and were led by the Perinatal Insti-
tute to support the implementation of GAP. These
meetings support implementation and provide a forum
for Trusts to share experiences and solutions. Research
meetings with site leads are being held throughout the
study period to ensure continued engagement with the
research project for provision of data for trial purposes.
Regular email correspondence and newsletters are dis-
tributed to all cluster sites.
Pre-specified requirements for cluster compliance with
GAP comprise: (1) identification of a local multidiscip-
linary GAP team; (2) a pre-specified proportion of staff
who have completed training and (3) confirmation that
local guidelines and audit are in line with GAP recom-
mendations. A minimum of 75% staff should receive
face-to-face training and be e-learning compliant. Both
the Perinatal Institute and the trial team will support
non-compliant clusters to discuss strategies to improve
compliance with GAP. If these clusters remain
non-compliant by the time of data collection, despite at-
tempts to comply, they will still be analysed as rando-
mised to GAP in the intention-to-treat analyses, but the
lack of compliance will be acknowledged in other ana-
lyses (see the ‘Analysis methods’ section).
Retention and compliance in units randomised to
standard care is maintained through regular contact via
site visits, newsletter and review of changes in clinical
guidelines which may have an impact on the detection
of SGA infants (e.g. implementation of the NHS England
Saving Babies’ Lives Care Bundle [5]).
Outcomes
The primary outcome of this study is antenatal ultra-
sound detection of SGA (after 24 completed weeks of
gestation) in infants who are also SGA at birth. In this
trial, we are focussed on the antenatal detection of those
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) table for the timeline of study enrolment, intervention
and assessment
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Fig. 3 Diagram of individual management within participating clusters
Fig. 4 NHS England protocol for screening small-for-gestational-age (SGA) foetuses
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infants who weigh less than the 10th centile for gestational
age on both population and customised growth charts at
birth (Fig. 5). This group of infants will be the denomin-
ator (SGA at birth) for the estimation of the detection rate
and will be determined using birthweight charts (GROW
customised chart and UK90 population chart) [29, 30].
Amongst these infants, the numerator (antenatal
ultrasound detection of SGA) will be defined as
ultrasound-derived estimated fetal weight < 10th centile by
customised charts in the GAP implementation arm and
by population charts in the standard care arm [29–31].
The key secondary outcomes are classified according to:
clinical outcomes, health-economic outcomes and out-
comes derived from process evaluation of the programme
implementation; see Table 2 for details. These outcomes
will be compared between the two arms of the trial during
a pre-specified period of minimum 4months which will
be referred to as the ‘trial outcome period’.
Sample size – power calculation
A minimum target sample size of 12 clusters (six per arm)
was set based on information collected during protocol
development. First, we assessed that the mean births per
cluster per year in a sample of London maternity Trusts
likely to participate in the trial was 5053. We assumed a
10% rate of SGA by a single definition. Pooled estimates
from previous studies suggest that 75% of SGA infants de-
fined by customised standards are also SGA by population
references and vice versa [19, 22, 32, 33]. Therefore, we
estimate a SGA rate by either definition (customised or
population) of 12.5% and 60% of these babies (7.5% of
total sample) will be SGA by both definitions (Fig. 5).
During the trial outcome period (minimum of 4
months) we anticipate a mean of 42 babies to be SGA
by customised standards only; 42 SGA by population
references only; and 126 SGA by both definitions per
cluster based on the assumptions above (see Distribution
– Table 3). Further details of this assumptions are pro-
vided in Additional file 1: Table S1-S2. However, we have
explored the impact on power of fewer babies meeting
both SGA definitions, defined as a mean of only 84 SGA
babies per cluster in the unlikely extreme scenario where
the number of infants in the overlap is reduced by a
third. Published reporting using detection during stand-
ard antenatal care suggest that, regardless of whether
population or customised standards are used to define
SGA at birth, around 20% of SGA births are detected
antenatally [11, 12, 17]. For the intervention arm (GAP
programme), we anticipate an improvement in our pri-
mary outcome from 20 to 33%.
We were unable to identify reports of an intra-cluster
correlation coefficient for detection of SGA; therefore, a
coefficient of the most approximate outcome (fetal
growth restriction) was used (0.019) [34]. A cluster size
of 126 SGA infants (by customised standards and popu-
lation references) and six clusters in each arm provides
84% power to demonstrate superiority of GAP at the
5% significance level (two-sided test) for our primary
outcome. In the alternative unlikely scenario of only
84 SGA infants by both definitions per cluster the de-
sign provides 79% power. Power calculations were
performed using the user-written programme clustersampsi
for Stata [35].
We also performed power calculations for two second-
ary outcomes. This sample size will also provide 91%
power to demonstrate a superiority of GAP in detecting
SGA defined by customised standards (increase in detec-
tion from 19 to 33%) and results in over 90% power to
demonstrate non-inferiority of the intervention for the
ultrasound detection of SGA by population references
(increase from 20 to 28%, considering an example
non-inferiority margin of 5%).
Data collection and management
Most data will be acquired from routine hospital sys-
tems. Data obtained either manually from clinical notes,
or electronically from hospital maternity and neonatal
databases will be entered/uploaded into the study data-
base. Data will be pseudonymised and linked to a study
identification number at each site before the pseudony-
mised data is sent electronically to the trial team. The
key connecting participant details to study identification
number will be password-protected and kept locally at
study sites on NHS networks.
Data collected during the study includes clinical data
from the period prior to implementation (baseline data)
and during the trial, together with rates of training com-
pliance. We will use a calculator provided by the Perinatal
Table 1 Recommended management of women in clusters
randomised to Growth Assessment Protocol (GAP)
Risk assessment for small for gestational age (SGA) (see Fig. 4) and
management as per the GAP protocol
• Women at low risk of SGA will be seen in antenatal clinic, where
standardised fundal-height measurements will be performed (2–3
weekly), starting from 26 to 28 weeks
• For women at high risk of SGA, serial ultrasounds will be recommended,
every 3 weeks starting from 26 to 28 completed gestational weeks
Customised fundal-height and ultrasound charts will be generated in
early pregnancy for all women using the gestation-related optimal weight
• (GROW) software. Both ultrasound generated estimated fetal weights
(EFWs) and fundal heights will be plotted on the customised chart
• Any deviation from expected progressive growth of fundal height on
these charts will raise a recommendation for fetal ultrasound measurement,
as will first plots below the 10th centile line
• Any deviation from expected growth on these charts from ultrasound
generated EFW measurements will prompt surveillance according
to the Royal College of Obstetricians and Gynaecologists (RCOG)
Investigation and Management of the Small-for-Gestational-Age Fetus
guidance [25]
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Institute (GROW calculator) [30], which determines cus-
tomised birthweight standards. A review of the fidelity of
GAP use will inform data monitoring and the implemen-
tation evaluation, and clinical and service use data will be
collected for a 4–6-month period after full GAP imple-
mentation, to assess primary and secondary outcomes of
this study.
For the process evaluation of implementation, quanti-
tative data (including proportion of staff trained/
assessed, women managed with the GAP programme,
missed-case audit) will be collected. Research staff will
also perform an audit of selected patient notes (women
in whom SGA was missed) to check for adherence to
risk stratification and management protocols.
Qualitative, semi-structured interviews with purposively
sampled key staff/stakeholders will be performed to assess
barriers and facilitators of implementing this complex
intervention. In addition, local policies or guidance for
antenatal management of associated conditions, or inter-
ventions, will be collated centrally (e.g. guidance on re-
duced fetal movements, policy for routine third-trimester
ultrasound or diabetes in pregnancy).
Analysis methods
Statistical analysis
The analysis will acknowledge the clustering of individ-
ual participants by centre. Due to the modest number of
clusters the analysis will be performed using a
cluster-summary statistic approach, i.e. calculating the
proportion with the primary outcome for each cluster
and comparing these values between intervention and
standard care arms and presenting 95% confidence inter-
vals for the average difference. Adjustment will be made
for key characteristics of the individual participants, e.g.
age, parity, ethnicity to account for imbalance between
arms that might occur from the randomisation of only a
modest number of clusters. An adjusted cluster sum-
mary value of the primary outcome will be generated for
each cluster for both the trial period and the baseline
(i.e. pre-trial) period. Then, an analysis of covariance
(ANCOVA) analysis will be conducted to compare inter-
vention and control clusters accounting for differences
at baseline. The primary analysis will be on a modified
intention-to-treat basis, in which any Trusts in the inter-
vention arm that did not contact the GAP provider to
initiate training and implement the intervention in the
study period due to changes in local strategy are ex-
cluded, since such changes are not considered inform-
ative concerning how GAP would have performed in the
Trust. In addition, we will conduct an intention-to-treat
analysis including all Trusts as randomised. This sen-
sitivity analysis will not be influenced by potential
differences between a Trust that is randomised to the
GAP arm but does not register to use it, compared to
those that do use it, which could confound the effect
estimate. A further secondary analysis will be conducted
Fig. 5 Proportion of small-for-gestational-age (SGA) babies defined by population references, customised standards or both
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under a per-protocol approach restricting analysis of the
intervention arm to clusters that complied with GAP
(as defined in the ‘Retention and compliance’ section).
Subgroup analyses will be performed to assess the
intervention effect amongst women who have had full
exposure to GAP (charts generated prior to 24 weeks’
gestation) and those women who have only had late
exposure (e.g. those women who transfer care to the
hospital after 24 weeks’ gestation). A detailed analysis
plan will be prepared before the analysis begins.
Health economic evaluation
A cost-effectiveness analysis will be carried out on the
primary clinical outcome (detection of SGA). This will
Table 3 Distribution of small for gestational age (SGA) and expected detection rates
Number of small-for-gestational-age (SGA) neonates/10,000 births according to pooled estimates
of previous studies [19, 22, 32, 33]
By population
reference only
By both population reference and
customised standards (primary outcome)
By customised standards
only
Total observations with SGA infants 250 750 250
Detection – standard care arm % 20% 20% 16%
N 50 150 40
Detection – implementation arm
(Growth Assessment Protocol; GAP)
% 12% 33% 33%
N 30 250 83
Table 2 Key secondary outcomes
Clinical outcomes Health-economic
outcomes
Process evaluation of
implementationAntenatal assessments Neonatal outcomes Maternal outcomes
Rate of antenatal ultrasound
detection of SGA at birth by
customised standards and by
population references.
Antenatal clinical detectiona
of SGAb.
Analysis of GAP diagnostic test
performance (specificity,
sensitivity, negative predictive
value, positive predictive value)b
Ultrasound assessment of SGA
using a different threshold, e.g.
5th centileb.
Growth trajectories (fetal biometry
and EFW) and Doppler parameters
in the detection of SGAb.
Comparison of GROW ultrasound
charts against standard population
charts on classification of fetal
growth (small for gestational age,
appropriate for gestational age,
large for gestational age)b
Basic parameters:
Gestational age at birth
Birthweight
Head circumference
Antenatal:
Length of stay in
hospital
Number of ultrasound
scans after 24 weeks
Antenatal clinic/antenatal
day unit activity
Rates of induction of
labour
Rates of caesarean sections
Length of maternal and
neonatal stay
Admissions and average
length of stay in NICU/
SCBU
Proportion of staff trained,
staff assessed and
women assessed with GAP
programme
Adherence to SGA risk
stratification and
management protocols
Adherence to missed-case
analysis
Evaluation of acceptability
and feasibility of intervention
to staff and women,
contextual barriers and
facilitators, practice in control
sites
Organisational impact and
unintended consequences
Condition at birth:
5-min Apgar score < 7
Arterial cord pH < 7.1
Any respiratory support given
at delivery
Intrapartum:
Induction of
labour
Mode of delivery
(including caesarean
section rates)
Postpartum
haemorrhage
Rates of 3rd or 4th
degree perineal tear
Neonatal admissions:
Length of stay at each neonatal
level of care
Neonatal morbidity:
Major neonatal morbidity (any
of neonatal brain injury, receipt
of supplemental oxygen at 28
days of age, Bell stage 2+
necrotising enterocolitis,
culture-positive sepsis,
retinopathy requiring ophthalmic
intervention)
Minor neonatal morbidity (any of:
hypothermia, hypoglycaemia,
nasogastric tube feeding)
Postnatal:
Length of stay in
hospital
Breastfeeding at
discharge
Perinatal loss:
Antepartum or intrapartum
stillbirth
Neonatal death (early or late)
Death before neonatal discharge
(after 28 days of birth)
Cause of death
Abbreviations: EFW estimated fetal weight, GAP Growth Assessment Protocol, GROW gestation-related optimal weight, NICU neonatal intensive care unit, SCBU
special care baby unit, SGA small for gestational age
aClinical detection of SGA is defined as ‘antenatal acknowledgement that the foetus is expected to weigh below the 10th centile at birth, by charts appropriate to
the study arm’
bThese secondary outcomes will not be reported in the first clinical paper; please see the section on ‘Presentation and publication strategy’
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evaluate probabilistically whether the intervention is un-
equivocally cost-effective compared to standard practice
(e.g. less costly and more effective), less cost-effective
(e.g. more costly and less effective) or whether GAP
achieves improved rates of SGA detection at greater cost
compared to standard practice.
The economic evaluation will draw on patient-level
clinical resource use (e.g. use of ultrasound) with data
extracted from the hospital records combined with data
on the primary clinical outcome to evaluate the
cost-effectiveness of GAP. National and locally applic-
able unit costs will be used to cost resource-use identi-
fied for each patient, and subsequently to evaluate the
difference between the pregnancy and neonatal care
costs, between the intervention and control sites. We
will also evaluate the impact of costs relating to add-
itional activities required for successful implementation
of the GAP protocol on conclusions regarding
cost-effectiveness, including the cost of training clinical
teams and on-going costs associated with monitoring
adherence to the GAP protocol.
The economic evaluation will be carried out from the
NHS hospital (NHS Trust) perspective and will, there-
fore, exclude measurement of wider resource use linked
to activities that are not undertaken by Trust maternity
or neonatal care teams, e.g. use of community-based pri-
mary care services. Resource use and cost impacts will
only be included in the evaluation up to the point of
postnatal inpatient discharge.
Analysis of implementation
The process evaluation aims to understand how the
GAP intervention works in practice, by examining im-
plementation, mechanisms of impact, and contextual fac-
tors. Implementation of the intervention will be evaluated
via a mixed-methods approach drawing on the UK
Medical Research Council framework for trials of complex
interventions [36, 37]. Following Steckler and Linnan’s
approach [38], the key dimensions of implementation to
be analysed include those detailed in Table 4.
We will describe the intervention and the mechanisms
through which it is expected to produce change in a
specific context using the Template for Intervention
Description and Replication (TIDieR) guidance [39] and
produce a logic model which informs data items for the
evaluation of implementation.
For process evaluation of implementation, descriptive
quantitative information on fidelity, dose and reach will
enable us to consider more detailed modelling of varia-
tions between participants or sites in terms of factors
such as fidelity or reach (e.g. are there ethnic or socio-
economic biases in who is reached?).
For evaluation of acceptability and feasibility of inter-
vention to staff and women, contextual barriers and fa-
cilitators and organisational impact, gathered through
qualitative data collected at six intervention sites. We
will also undertake qualitative interviews at control (de-
layed implementation) sites, to explore whether mea-
sures similar to the GAP intervention have been
adopted, perhaps as part of the NHS England ‘Stillbirth
Care Bundle’.
Data monitoring
Data Monitoring Committee
A joint Trial Steering and Data Monitoring Committee
(TSC/DMC) has been formed. It will meet halfway
through the trial to review the progress of the trial, any
adverse events and the proposed analysis plan. At the
end of the trial, it will meet to review the proposed trial
outputs. There is no planned interim analysis of the trial
outcomes, and outcome data will only be analysed at the
end of the trial.
Monitoring for potential harms
The non-medicinal intervention being tested in this trial
is not expected to have side effects and is already widely
adopted across the UK. Nevertheless, we shall monitor
for harms due to the intervention, or its implementation
within the trial, as for the sites concerned this is a new
method of patient care. The intervention comprises
measurement of fundal height and prompt referral for
ultrasound where needed. Side effects of fundal-height
measurement may consist of maternal discomfort due to
the semi-recumbent position required and discomfort
due to increased skin sensitivity. Ultrasound is a mechan-
ical wave and can theoretically increase the temperature
in the studied tissue. The Doppler ultrasound uses higher
energy and focusses on a smaller volume of tissue,
Table 4 Dimensions of implementation for analysis [38]
Dimension Description
Implementation process The structures, resources and mechanisms through which delivery is achieved
Fidelity The consistency of what is implemented with the planned intervention
Adaptations Alterations made to an intervention to achieve better contextual fit
Dose How much intervention is delivered
Reach The extent to which a target audience encounters the intervention
Mechanisms of impact The intermediate mechanisms through which intervention activities produce intended (or unintended) effects
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resulting in greater changes in temperature. In a clinical
obstetric scenario, however, the increase in temperature is
less than 1 °C, which is not considered clinically signifi-
cant. The World Health Organisation performed a sys-
tematic review of 61 publications on the subject and
reported no association with adverse maternal, fetal and
neonatal outcomes [40]. Both components of the inter-
vention are used in different levels in routine care; there-
fore, any of the above cannot be strictly assigned to the
intervention.
Adverse events may occur and may be attributed to in-
correct use of the GAP programme. As an example, mis-
takes in the manual plotting of fundal height on any
chart could lead to missed referrals and ultimately the
potential for a serious adverse event (SAE). The audit of
missed SGA cases and the review of all stillbirth cases
will be performed locally in each cluster as recom-
mended by GAP. Any event associated with misuse of
GAP will be reported as an adverse event in the trial.
Any serious adverse events recognised by the sites be-
cause of the intervention (which result in death,
life-threatening conditions or prolonged hospitalisation)
must be reported to the sponsor within one working day
of the investigator becoming aware of the event. Both
the site clinical team and the sponsor should investigate
the SAE for causality. The trial team will also record in-
stances of concerns raised by either staff or participants
at intervention sites relating to the intervention or how
it is implemented.
Presentation and publication strategy
The primary and selected secondary maternal and neo-
natal outcomes will be published together in the first
paper (see Table 2). Further papers will be submitted for
publication for the detailed health-economic analysis, im-
plementation evaluation, analysis of alternative methods
of measuring detection of growth restriction and add-
itional subgroup analyses.
Discussion
This study will provide the first evidence from a RCT
into the effect of implementing the GAP programme,
compared to standard care, on the identification of SGA
measured by ultrasound scan. The study is powered for
detection of SGA babies, and not for stillbirth rates. Al-
though a study to show differences in stillbirth is ultim-
ately desirable, it is unfortunately not feasible to power
such a trial [41] due to the infrequency of this event and
hence very large sample size required. It is widely recog-
nised that antenatal detection of SGA is associated with
reduction in stillbirth rates [10].
The primary outcome for this trial has been chosen
following consensus agreement from the co-investigators
and independent reviewers. It is recognised that there is
an overlap between SGA defined by customised and
population standards. The group of infants meeting cri-
teria for both definitions are at the highest risk of mor-
bidity/mortality [19]. Detection of these babies is crucial.
Focussing on this overlapping group addresses the issue
that GAP was not developed to detect SGA by popula-
tion standards, and vice versa.
Customised standards have been criticised because
some factors (namely maternal weight and ethnicity)
might contribute to differences in birth weights due to
pathological, rather than physiological, mechanisms [32,
42, 43]. The Perinatal Institute recommends the adjust-
ment for maternal weight based on their report that, in
women with a Body Mass Index (BMI) within the normal
range (20–25 kg/m2), variation in maternal weight was not
associated with increased risk of perinatal mortality. In
women with BMI > 25 kg/m2, the rate of perinatal mortal-
ity was correlated with SGA using customised standards
but not population references [44]. However, cause-spe-
cific perinatal mortality may differ by maternal BMI. The
influence of ethnicity is more complex due to the known
association between ethnicity and socioeconomic
deprivation [45–47], which is associated with antepartum
stillbirth risk [48, 49]. The INTERGROWTH-21st study
recruited low-risk, well-nourished women of optimal
health, education and socioeconomic status in urban sites
with low levels of pollutants [50] and showed similarities
in fetal growth (as assessed by head circumference) and
newborn length in those pregnancies studied across eight
international and multi-ethnic sites. In contrast, work
using the Canadian Stillbirth Registry reported that when
using population standards, women of Chinese and South
Asian ethnicity have higher rates of SGA, when compared
to native ethnicities, but lower rates of perinatal mortality.
In the same group, the rate of SGA was lower and con-
cordant with the prevalence of perinatal mortality when
neonates were assessed using customised, rather than
population growth, standards [51]. More recently, the
World Health Organisation has published new fetal
growth charts that do acknowledge differences in fetal
growth between women of different ethnicities, heights,
weights, ages and parity [52]. According to this evidence,
adjustment for ethnicity may improve the detection of
SGA infants at risk of morbidity and mortality, irrespect-
ive of any indirect adjustment for the pathological influ-
ences such as socioeconomic conditions.
In the UK, there is a high-level ambition to reduce the
rate of stillbirths, arising from the RCOG and the De-
partment for Health [4, 6]. Maternity clinical networks
and local maternity systems are currently recommending
several interventions aimed at reducing rates of stillbirth
in the UK [5]. One theme of the national stillbirth rec-
ommendations is reduction of SGA-related stillbirth by
improved detection of SGA. The GAP programme is the
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most widely adopted of the available potential solutions,
leaving few available sites for recruitment into this trial.
We therefore also face the last opportunity to conduct a
prospective randomised trial of customised growth
charts and the GAP protocol in the UK. Finally, other
national initiatives to reduce stillbirth include policies to
support smoking cessation, improve intrapartum fetal
monitoring and increase reporting of reduced fetal
movements [5]. Uptake of smoking cessation support is
anticipated to impact upon rates of SGA infants, which
could affect analysis of our primary outcome, and all ini-
tiatives may impact upon several of the secondary out-
comes in this trial. Hospitals recruited to both arms of
the trial are under external pressure to adopt some of
these policies. We are collecting information on all pol-
icies introduced which are independent of the interven-
tion during the trial period to evaluate any potential
effect of contamination.
Regarding the health-economic analyses, we have con-
sidered the usefulness of reporting the costs from a
Trust or health service perspective. The current UK pay-
ment system uses tariffs, according to a low-/high-risk
stratification of individual patients, rather than crude
costs for work done. Whilst this will allow us to calcu-
late the cost of the GAP programme to the health ser-
vice (by estimating any changes to the likely tariff
distribution because of GAP), it does not necessarily
translate into financial cost to the hospitals themselves
from providing resources to implement GAP, or from
the implications of implementing GAP on the patients/
resources (by affecting rates of SGA diagnosis). This jus-
tifies our approach of reporting the health-economic
analysis from a Trust perspective.
Regarding the implementation analysis, we anticipate
variation between clusters in GAP implementation, in-
cluding local adaptations to suit available resources (e.g.
number of sonographer lists, and the financial resources
required to implement the programme). Such variations
will need to be placed in context when assumptions are
made about external validity. Nevertheless, the implemen-
tation study should produce documented evidence of such
differences, and by examining these in relation to the logic
model produced for the study, we hope to extend under-
standing of how variations in implementation might affect
the impact of GAP in real-world situations.
Overall, we aim to provide high-quality evidence,
through a RCT, of the performance and service provision
requirements of the GAP protocol. This may have the po-
tential to inform national policy decisions on methods to
reduce the rate of stillbirth.
Trial status
The first eight cluster sites were randomised to either
the intervention or control arm on 3 November 2016. A
further three sites were randomised in December 2016
and the final two sites randomised in July 2017. Baseline
audit and training procedures were then required prior
to the use of the intervention in the active clusters. The
first cluster sites began to use the intervention in Octo-
ber 2017 and we anticipate that the intervention will
continue to be applied to women attending for maternity
care at those sites, with the last women to be included
in the data collection likely to have the intervention ap-
plied in early July 2018. Data will be collected on all ba-
bies being born between 1 June and 31 November 2018.
Additional file
Additional file 1: Table S1. Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) Checklist (2013): recommended items to
address in a clinical trial protocol and related documents. Table S2.
Distribution of small-for-gestational-age (SGA) and expected detection
rates. (DOCX 41 kb)
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